再鼎医药:2024年业绩略超预期 2025年指引超预期

中金公司
03 Mar

2024 年业绩略超我们预期公司公布2024 年业绩:收入3.99 亿美元,同比增长50%,归母净亏损2.57 亿美元,业绩略超我们预期,主因艾加莫德销售高增长。公司指引2025 年收入5.6 亿-5.9 亿美元,并有望于4Q25 实现non-GAAP 经营利润扭亏,超过我们预期。发展趋势艾加莫德带动收入略超预期。24 年公司实现产品收入3.98 亿美元,同比增长49%,其中艾加莫德收入9,360...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10